Neoven
Phase 3Small molecule
Neoven is one of 24 small molecule programs targeting Hemorrhoid. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Botox
RRevance Therapeutics, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Marcaine
IInnocoll
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Kenalog
BBassett Healthcare
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Celestone
SSchering-Plough
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemorrhoid1 trial
Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids
Recruiting·SSultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey·Phase 4·NCT07128979·250 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Neoven. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details